DNA hypomethylation-activated PRAME drives early-stage lung adenocarcinoma recurrence via ZNF740 and PI3K/AKT/mTOR signaling.

Transl Lung Cancer Res · 2026 · PMC13186639 · PMID 42170260

Europe PMC DOI

hedged sentence

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

marginally significantP=0.067so close (0.05 < p ≤ 0.1)

However, we further explored disease-free survival (DFS) in early-stage (n=162), and the result suggested that higher expression of PRAME was marginally significant (P=0.067) related to higher recurrence ( Figure S2C ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.